Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China · Delayed Price · Currency is CNY 33.78
-0.27 (-0.79%)
Feb 13, 2026, 3:00 PM CST
SHA:688076 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,898 | 1,623 | 1,033 | 648.03 | 641.71 | 564.99 |
Other Revenue | 1.99 | 1.99 | 0.82 | 3.26 | 2.16 | 1.89 |
| 1,900 | 1,625 | 1,034 | 651.29 | 643.87 | 566.87 | |
Revenue Growth (YoY) | 20.52% | 57.21% | 58.69% | 1.15% | 13.58% | 52.58% |
Cost of Revenue | 672.46 | 575.05 | 444.27 | 307.94 | 306.3 | 249.55 |
Gross Profit | 1,227 | 1,050 | 589.28 | 343.36 | 337.57 | 317.32 |
Selling, General & Admin | 388.8 | 339.13 | 268.23 | 186.98 | 150.49 | 120 |
Research & Development | 241.25 | 227.45 | 124.89 | 69.47 | 63.09 | 60.53 |
Other Operating Expenses | 2.66 | 1.7 | 0.02 | 9.25 | 5.24 | 3.65 |
Operating Expenses | 643.59 | 588.89 | 398.25 | 271.58 | 220.47 | 185.87 |
Operating Income | 583.68 | 460.86 | 191.04 | 71.78 | 117.1 | 131.45 |
Interest Expense | -56.91 | -34.75 | -16.09 | -9.26 | -6.12 | -11.63 |
Interest & Investment Income | 12.35 | 9.05 | 9.11 | 28.54 | 8.38 | 7.16 |
Currency Exchange Gain (Loss) | 8.68 | 8.68 | -1.38 | 1.03 | -1.58 | -7.73 |
Other Non Operating Income (Expenses) | 2.48 | -0.58 | -0.47 | -0.3 | -0 | -1.12 |
EBT Excluding Unusual Items | 550.28 | 443.26 | 182.22 | 91.79 | 117.78 | 118.14 |
Impairment of Goodwill | - | - | - | - | -1.28 | - |
Gain (Loss) on Sale of Investments | 0.85 | -2.79 | 0.26 | -1.96 | 0.13 | - |
Gain (Loss) on Sale of Assets | -9.17 | -9.2 | -15.06 | 18.44 | -0.97 | -4.12 |
Asset Writedown | -13.05 | - | - | - | - | - |
Other Unusual Items | 15.8 | 7.24 | 5.71 | 14.9 | 10.07 | 32.55 |
Pretax Income | 544.71 | 438.5 | 173.13 | 123.16 | 125.73 | 146.56 |
Income Tax Expense | 49.29 | 38.69 | 7.67 | 0.39 | 16.92 | 26.53 |
Earnings From Continuing Operations | 495.43 | 399.82 | 165.45 | 122.77 | 108.81 | 120.03 |
Minority Interest in Earnings | 3.26 | 4.57 | -2.52 | 6.34 | 6.58 | 3.41 |
Net Income | 498.69 | 404.39 | 162.94 | 129.11 | 115.39 | 123.44 |
Net Income to Common | 498.69 | 404.39 | 162.94 | 129.11 | 115.39 | 123.44 |
Net Income Growth | 18.32% | 148.19% | 26.20% | 11.89% | -6.52% | 153.94% |
Shares Outstanding (Basic) | 309 | 301 | 300 | 296 | 269 | 224 |
Shares Outstanding (Diluted) | 309 | 308 | 300 | 296 | 269 | 224 |
Shares Change (YoY) | -1.74% | 2.52% | 1.28% | 10.06% | 19.95% | -1.06% |
EPS (Basic) | 1.61 | 1.34 | 0.54 | 0.44 | 0.43 | 0.55 |
EPS (Diluted) | 1.61 | 1.31 | 0.54 | 0.44 | 0.43 | 0.55 |
EPS Growth | 20.41% | 142.09% | 24.60% | 1.66% | -22.07% | 156.65% |
Free Cash Flow | -946.61 | -690.01 | -310.43 | -409.07 | -52.61 | 30.1 |
Free Cash Flow Per Share | -3.06 | -2.24 | -1.03 | -1.38 | -0.20 | 0.13 |
Dividend Per Share | 0.572 | 0.643 | 0.286 | 0.143 | 0.107 | - |
Dividend Growth | 60.04% | 125.03% | 99.93% | 33.43% | - | - |
Gross Margin | 64.60% | 64.61% | 57.02% | 52.72% | 52.43% | 55.98% |
Operating Margin | 30.73% | 28.36% | 18.48% | 11.02% | 18.19% | 23.19% |
Profit Margin | 26.25% | 24.89% | 15.77% | 19.82% | 17.92% | 21.78% |
Free Cash Flow Margin | -49.83% | -42.47% | -30.04% | -62.81% | -8.17% | 5.31% |
EBITDA | 838.15 | 662.75 | 322.81 | 170.52 | 198.73 | 202.16 |
EBITDA Margin | 44.12% | 40.79% | 31.23% | 26.18% | 30.87% | 35.66% |
D&A For EBITDA | 254.47 | 201.88 | 131.77 | 98.75 | 81.63 | 70.71 |
EBIT | 583.68 | 460.86 | 191.04 | 71.78 | 117.1 | 131.45 |
EBIT Margin | 30.73% | 28.36% | 18.48% | 11.02% | 18.19% | 23.19% |
Effective Tax Rate | 9.05% | 8.82% | 4.43% | 0.32% | 13.46% | 18.10% |
Revenue as Reported | 1,900 | 1,625 | 1,034 | 651.29 | 643.87 | 566.87 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.